The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.

[1]  D. Bauer,et al.  Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism , 2009 .

[2]  D. Generali,et al.  Increased antiresorptive activity of zoledronic acid (Z) administered in the night as compared to morning administration in breast cancer (BC) patients with bone metastases. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  E. Wagner,et al.  The Molecular Clock Mediates Leptin-Regulated Bone Formation , 2005, Cell.

[4]  M. Maricic,et al.  Clinical use of serum and urine bone markers in the management of osteoporosis , 2005, Current medical research and opinion.

[5]  A. Lipton.  Management of bone metastases in breast cancer , 2005, Current treatment options in oncology.

[6]  J. Gralow.  Optimizing the treatment of metastatic breast cancer , 2005, Breast Cancer Research and Treatment.

[7]  R. Coleman.  The role of bisphosphonates in breast cancer. , 2004, Breast.

[8]  J. Takahashi,et al.  Mammalian circadian biology: elucidating genome-wide levels of temporal organization. , 2004, Annual review of genomics and human genetics.

[9]  M. Seibel,et al.  Markers of Bone Remodeling in Metastatic Bone Disease , 2003 .

[10]  M. Stockler,et al.  Bisphosphonates for breast cancer. , 2005, The Cochrane database of systematic reviews.

[11]  G. Mundy.  Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.

[12]  C. Christiansen,et al.  Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. , 2002, Bone.

[13]  C. Christiansen,et al.  Mechanism of circadian variation in bone resorption. , 2002, Bone.

[14]  S. Mohan,et al.  Circadian and longitudinal variation of serum C-telopeptide, osteocalcin, and skeletal alkaline phosphatase in C3H/HeJ mice. , 2001, Bone.

[15]  P. Vestergaard,et al.  Loop diuretics alter the diurnal rhythm of endogenous parathyroid hormone secretion. A randomized‐controlled study on the effects of loop‐ and thiazide‐diuretics on the diurnal rhythms of calcitropic hormones and biochemical bone markers in postmenopausal women , 2001, European journal of clinical investigation.

[16]  F. Lévi,et al.  Circadian chronotherapy for human cancers. , 2001, The Lancet. Oncology.

[17]  R. Eastell,et al.  Bone Markers: Biochemical and Clinical Perspectives , 2001 .

[18]  M Heer,et al.  Space flight is associated with rapid decreases of undercarboxylated osteocalcin and increases of markers of bone resorption without changes in their circadian variation: observations in two cosmonauts. , 2000, Clinical chemistry.

[19]  H. Kraemer,et al.  Diurnal cortisol rhythm as a predictor of breast cancer survival. , 2000, Journal of the National Cancer Institute.

[20]  S. Cerutti,et al.  Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. , 1999, Clinical chemistry.

[21]  S. Leigh,et al.  Comparison of analytical performance and biological variability of three bone resorption assays. , 1997, Clinical chemistry.

[22]  J. Lin,et al.  Bisphosphonates: a review of their pharmacokinetic properties. , 1996, Bone.

[23]  P. Delmas,et al.  Biochemical markers of bone turnover , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  S. Leyvraz,et al.  Pharmacokinetics of pamidronate in patients with bone metastases. , 1992, Journal of the National Cancer Institute.

[25]  M. Burritt,et al.  Abnormalities in circadian patterns of bone resorption and renal calcium conservation in type I osteoporosis. , 1992, The Journal of clinical endocrinology and metabolism.

[26]  K. Mann,et al.  Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease. , 1988, The Journal of clinical endocrinology and metabolism.

[27]  J. Kanis,et al.  An estimate of the turnover rate of bone-derived plasma alkaline phosphatase in Paget's disease. , 1975, Clinica chimica acta; international journal of clinical chemistry.